ABSTRACT Alloantisera directed against chicken class I MHC (BFIV) antigens were produced by using transfected cell lines expressing cloned BFIV sequences. The cloned BFIV sequences were from haplotypes *12, *13, and *21. Two laboratory-derived class I mutant sequences (BFIV13m126 and BFIV21m78) were developed to analyze cross-reactive epitopes and to induce specific alloantisera. Antisera were tested in hemagglutination and flow cytometry assays. The antisera produced were highly specific and had minimal cross-reactivity. The antisera induced by the BFIV21m78 mutant confirmed the significance of amino acids 78 and 81 in cross-reactivity
INTRODUCTION
The chicken MHC (B-complex) is comprised of three classes of highly polymorphic loci, i.e., class I (B-F), class II (B-L), and class IV (B-G). The class I and class II molecules are structurally and functionally equivalent to their mammalian counterparts (Guillemot and Auffray, 1989) . However, the highly polymorphic B-G molecules have no mammalian equivalent. They were initially found only on erythrocytes (red blood cells, RBC) and their precursors (Longenecker and Mosmann, 1980; Miller et al., 1984; Salomonsen et al., 1987) . B-G-like molecules have since been found on various cells of the immune system including thrombocytes (avian platelets), peripheral B and T lymphocytes, bursal cells, and thymocytes . At least 18 B-G loci have been identified . The function of these molecules is unknown.
A second cluster of polymorphic class I and class II loci (referred to as Rfp-Y) has been identified that segregates independently of the traditional B-complex (Briles et al., 1993; Miller et al., 1994) . Some of these genes have been The production of antiserum using BFIV-expressing cell lines is covered under US patent no. 6075125. To whom correspondence should be addressed: baconld@msu.edu.
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between haplotypes B*21 and B*5. The highly specific antisera were tested by hemagglutination on red blood cells of 31 different MHC haplotypes. The consistency of hemagglutination patterns and minimal cross-reactivity demonstrated that these BFIV antisera are extremely valuable in defining MHC haplotype in various chicken lines. Because of the extreme low level of recombination between the chicken class I and class II loci, identification of BFIV allele can be used to define MHC haplotype within a line. Complete identity between the transfected cell line and the chicken used to produce the antiserum is required to ensure the monospecificity.
shown to be expressed and involved with skin-graft rejection (Pharr et al., 1996) , but their role in immune response is uncertain. A significant influence of Rfp-Y on Marek's disease resistance has been reported for some genetic stocks (Wakenell et al., 1996) but not others Lakshmanan and Lamont, 1998) .
The chicken MHC haplotype is defined by using alloantisera in a hemagglutination (HA) assay. Twenty-seven serologically defined haplotypes were identified in an international workshop . However, haplotype determination can be very complex because alloantisera show extensive cross-reactivity . Even alloantisera produced within MHC-congenic birds can result in complex cross-reactions between haplotypes (Fulton et al., 1996) . The presence of the immunogenic and polymorphic B-G molecules, the occurrence of either identical alleles or similar antigenic epitopes between B haplotypes Fulton et al., 1995 Fulton et al., , 1996 Fulton et al., unpublished) , and the unknown influence of the independently segregating Rfp-Y loci may have all contributed to the complexity of MHC serological patterns.
The use of B-G/B-F recombinants can allow the generation of B-F specific alloantisera (Simonsen et al., 1980) . However, recombination within the chicken MHC is very Abbreviation Key: ALV = avian leukosis virus; HA = hemagglutination; ISU = Iowa State University; MLF = mean log fluorescent; PBL = peripheral blood leukocytes; RBC = red blood cells; SBI = specific binding index; UCD = University of California at Davis; WBC = white blood cells. infrequent, resulting in only a limited set of recombinants Hala et al., 1988) . A limited number of monoclonal antibodies have been produced that either detect monomorphic determinants or react with only certain haplotypes (Longenecker and Mosmann, 1981; Crone et al., 1985; Pink et al., 1985) .
Class I cDNA sequences from several haplotypes have been cloned and sequenced (Kroemer et al., 1990; Kaufman et al., 1992; Hunt et al., 1994; Pharr et al., 1994; Fulton et al., 1995a; Hunt and Fulton, 1998) . The sequence from the BFIV locus allele 21 has been shown to be expressed and functional . We describe here the production of B-F-specific alloantisera by using cloned class I (BFIV) cDNA sequences inserted into an avian retroviral expression vector. An avian B-cell line expressing the transfected class I cDNA gene products was used as the immunogen and resulted in the production of highly specific and very useful BFIV-specific alloantisera. These antisera allow serological definition of BFIV alleles in various lines and types of chickens without the complexity of extensive cross-reactions to B-G antigenic differences. Furthermore, these highly specific antisera detected epitope similarities in BFIV molecules between various defined MHC haplotypes. The ability of this method to produce B-F-specific antisera in an otherwise antigenically MHCidentical environment (i.e., B-G and other MHC antigens do not differ) is in apposition with the hypothesis that B-G antigenic differences are required for B-F antibody elicitation (Hala et al., 1981; Salomonsen et al., 1991) .
MATERIALS AND METHODS

Chicken Lines and Cell Lines
The development of the 15.B congenic lines has been previously described (Shen et al., 1984; Bacon et al., 2000 . Several additional UCD congenic lines were tested that contain haplotypes originally derived from unusual sources. The B*Q haplo-4 Invitrogen, San Diego, CA. type was obtained from the red Jungle Fowl and the B*O and B*C haplotypes were obtained from Ceylonese Jungle Fowl (Abplanalp, 1992) . Blood samples were also obtained from highly inbred chicken lines at Iowa State University (courtesy of S. J. Lamont). Thirteen B homozygous haplotypes in different inbred lines were tested (Chen and Lamont, 1992 A lymphoblastoid B-cell line RP9 (Okazaki et al., 1980 ) was used for expression of the various BFIV constructs and immunizations for antisera production. The RP9 cell line was originally developed from a bursal tumor from a 15I 5 × 7 2 F 1 chicken infected with subgroup B avian leukosis virus (ALV). Cell culture conditions and transfection procedures were described by Fulton et al. (1995) . The cells were harvested, washed in PBS, and used in the immunization scheme described. Immunization was performed in 15I 5 × 7 1 F 1 (series D) and 15I 5 × 7 2 F 1 (series E) chickens. The highly inbred lines 15I 5 , 7 1 , and 7 2 have been previously described (Bacon et al., 2000) . Line 15I 5 is homozygous for MHC haplotype B*15 and lines 7 1 and 7 2 (which are both sublines of line 7) are homozygous for B*2.
Development of the BFIV Expression Constructs
Cloning of the BFIV sequences has been described in detail (Hunt et al., 1994) . In brief, cDNA was produced from bursal mRNA obtained from 15I 5 B congenic birds homozygous for either the B*12, B*13, or B*21 haplotype. Polymerase chain reaction amplification of the cDNA by using primers specific for BFIV resulted in amplification of BFIV cDNA (Hunt et al., 1994; Fulton et al., 1995) . The 1,274-bp product was initially inserted into the pRC-CMV eukaryotic expression vector. 4 The avian retroviral vector used for expression in chicken cells was RCASBP(A) (Hughes et al., 1987) . Manipulation of the BFIV sequences for cloning into RCASBP(A) and optimal expression was described by Fulton et al. (1995; and unpublished) . The endogenous poly-A signal of the BFIV sequence was removed because this can interfere with subsequent retroviral expression. In addition, a ClaI site present in exon 4 (alpha 3 domain) was altered to assist in the transfer of the BFIV sequence into the RCAS-BP(A) vector. This change did not affect the subsequent amino acid sequence. At the junction of exons 1 and 2, a sequence encoding the epitope tag FLAG was inserted (described by Fulton et al., 1995) . The following two mutant FIGURE 1. The map of the BFIV FLAG construct depicting the location of the coding region for FLAG inserted between the coding sequence for the signal peptide and the coding sequence for the first amino acid (AA# 1) of the cell surface-expressed BF glycoprotein is shown. The location of the coding sequence for the mutated amino acids (AA# 78, 81, 126, 127, and 128 ) is also shown. The restriction enzyme sites (SacI and Bpu1102I) used for cloning the site-directed changes in the α-one and two domains along with the sites (ClaI, HindIII, and XbaI) used for insertion into RCASBP are shown. Exons 4 through 8, which encode the α-3, transmembrane, and cytoplasmic domains, are shown as one segment for simplicity.
BFIV sequences previously developed were also used in this study: BFIV21m78 and BFIV13m126 (Fulton et al.; unpublished) . Expression of the inserted BFIV sequences was confirmed by flow cytometry by using the FLAG epitope tag. Figure 1 shows the components of the BFIV constructs within the RCASBP(A) vector. Each construct contains exon 1 from the BFIV*21 haplotype and the FLAG coding sequence. Exons 2 and 3 (encoding the alpha 1 and alpha 2 domains) are from either the B*12, B*13, or B*21 haplotypes or from one of the mutant BFIV sequences. Exon 4 (alpha 3 domain) is from BFIV*21 but with the altered ClaI site. Exons 5, 6, 7, and 8 (cytoplasmic and transmembrane domains) are unaltered from the BFIV*21 sequence.
Five different cell lines were developed by using the BFIV constructs and the RP9 cell line. Three cell lines were produced that expressed either BFIV*12, BFIV*13, or BFIV*21. Two mutant BFIV-expressing cell lines were produced (Ho et al., 1989) (Figure 2 ). In the BFIV13m126 mutant construct, the amino acids in positions 126, 127, and 128 were altered from the D (aspartic acid), M (methionine), and K (lysine) found in BFIV*13 to G (glycine), T (threonine), and M (methionine) found in BFIV*12. The BFIV21m78 mutant construct has been previously described and has amino acids 78 and 81 altered from the D (aspartic acid) and R (arginine) found in BFVI*21 and BFIV*5 to the G (glycine) and E (glutamic acid) found in BFIV*2 and *15.
Production of Antisera
Two series of birds consisting of 25 birds each were immunized with the cell lines described above. Series D were birds from a cross of line 15I 5 and 7 1 and are therefore B*2/*15 heterozygotes, whereas the series E birds were from a cross of lines 15I 5 and 7 2 (also B*2/*15 heterozygotes). Birds were immunized with 1 × 10 7 cells starting at 7 to 10 wk of age. Immunizations were done twice per week for 15 wk in series D, and in series E for 3 wk followed by eight weekly injections. Within each series, five birds were immunized with each cell line expressing the BFIV constructs. Blood was collected weekly starting 4 wk after immunization. Sera were obtained from the clotted blood after 4-h incubation at room temperature. RBC were removed by centrifugation and antiserum was frozen at −20 C.
HA Assay
The HA assay has been described in detail by Fulton et al. (1995b) . For the titration assay, each antiserum was serially diluted twofold from 1/2 to 1/2,048 in U-shaped bottom, 96-well microtiter plates in PBS containing 0.5% chicken serum. An equal volume of a 0.5% suspension of packed RBC was mixed with the diluted antibody and incubated for 1 to 3 h at room temperature. The cells were FIGURE 2. The locations of the BFIV amino acid mutations are shown on the ribbon diagram for BFIV (α-one and two domains) modeled by using the crystal structure of human leukocyte antigen. resuspended, incubated overnight at 4 C and then scored. The greatest antibody dilution at which agglutination was visible as a lawn of cells on the well bottom was designated as the HA titer. Titers were expressed as the reciprocal of log 2 . For classification of antiserum reactivity with various haplotypes, antisera were serially diluted from 1/8 to 1/ 512 and scored as described above.
Flow Cytometry
Blood from mature birds of each homozygous haplotype was collected in Alsevier's solution (114 mM dextrose, 27 mM sodium citrate, 71 mM NaCl, pH 6.1). RBC were stored overnight at 4 C. White blood cells (WBC) were isolated over a Histopaque 5 gradient, washed three times in PBS, and stored overnight at 4 C. The flow cytometry procedure has been previously described (Fulton et al., 1996) . In brief, antiserum was diluted to 1/100 and incubated with 1 × 10 6 cells. After washing, the cells were incubated with fluorescein-labeled anti-chicken IgG (with IgM cross-reactivity), 6 washed, and resuspended in 300 µL of PBS + 0.1% NaN 3 with 20 µL of 1/100 dilution of saturated propidium iodide. Dead cells were omitted by propidium iodide exclusion. Five thousand viable cells were analyzed per sample on a FACSort 7 flow cytometer and the mean log fluorescent (MLF) channel number was obtained for each sample. The relative level of antibody binding on each cell type (specific binding index, SBI) was determined by using the following formula:
The two negative controls for each sample were from the mean log fluorescence of antisera with cells of lines 15I 5 (B*15) and 7 1 or 7 2 (B*2). An alloantiserum directed against B*21 and produced in a B*2/*15 heterozygous bird (7283) was used as a positive control for flow cytometry assays (Fulton et al., 1996) . pressing cell line agglutinated B*12 cells and also had a lower level of reactivity with RBC from the B*13 haplotype. All other haplotypes showed no HA with the BFIV*12-induced sera. Similar results were seen with the BFIV*13-induced alloantisera; RBC of the B*13 haplotype were agglutinated and a lower reactivity was seen with RBC of the B*12 haplotype. Antisera induced by the B*13m126 mutant also agglutinated RBC from both B*12 and B*13 haplotypes but with a lower mean titer. The BFIV*21-induced antisera agglutinated RBC from the B*21 haplotype and showed strong cross-reactivity with the B*5 haplotype RBC. The BFIV*21m78-induced antiserum was also positive for B*21 RBC and showed negligible cross-reactivity with B*5 RBC. Occasional low-level cross-reactivity (<1.0) was seen, reflecting reactivity of one of the five antisera at the highest concentration of a 1:2 dilution. Mean HA titer values below 1.0 were considered to be negative. The D series antisera all reacted very strongly to RBC from the line 7 2 , with HA titers ranging from 5.6 to 8.2, but were negative on RBC from all other chicken lines maintained at the Avian Disease and Oncology Laboratory (data not shown). The E series antisera were also tested and showed the same patterns of reactivity with similar titers on the various RBC haplotypes tested. One exception was that RBC of the line 7 2 were negative for all E series antisera (data not shown).
RESULTS
Specificity of the BFIV Alloantisera
Samples of the D series antisera, and RBC from line 7 2 , were analyzed extensively by W. E. Briles (Northern Illinois University). The results suggested that the antigenic differences between line 7 1 (used for D series antisera) and 7 2 (used for E series antisera and as a parent for the RP9 cell line) and other lines at the Avian Disease and Oncology Laboratory were due to differences in alleles at the J blood locus (W. E. Briles, 1995, personal communication) .
To further examine the specificity of the antisera, one serum from each immunization of the D and E series was tested by flow cytometry on RBC and WBC of the 15.B congenic haplotypes and from line 7 2 (Table 2 ). The SBI of one D series antiserum induced by each of the five BFIV constructs on cells of each homozygous haplotype is shown. With RBC, the patterns of specific binding and cross-reactivity are similar to those seen with HA. Even the low-level agglutination seen with the D series BFIV*21m78 antisera on B*5 and B*19 cells is reflected in the flow cytometry data. Each of the D series antisera also had a high SBI on RBC from line 7 2 , reflecting the HA of RBC by this antisera. Absorption of the BFIV*13-induced sera with the RP9-BFIV*12-expressing cell line resulted in elimination of most of the antibodies specific for B*12 cells but left B*13-specific antibodies. This absorption also removed antibodies specific for the line 7 2 RBC.
The flow cytometry data with WBC also shows the same cross-reactivity patterns as observed in the HA data within the 15.B congenic lines. However, reactivity of the D series antisera to WBC from line 7 2 was seen with only one antiserum (BFIV*12 specific) and at a very low level compared with the RBC flow cytometry data and the HA titer. The other D series antisera had nominal SBI values on line 7 2 WBC. All of the E series antisera showed similar Titer is given as the mean of the reciprocal of the highest reacting log 2 dilution of five antisera; nd = no data.
reactivity patterns in the flow cytometry assay to the D series antisera except that there was no reactivity with cells from the line 7 2 (data not shown).
Specificity of BFIV Antisera for Additional B-haplotypes
The use of BFIV-specific antisera in HA of RBC from chickens of various lines and MHC haplotypes is summarized in Table 3 . The standard Avian Disease and Oncology Laboratory line B-haplotypes were tested at the same time for comparisons and as internal controls. For this assay, the strength of the HA reaction is indicated af follows: ++ = very strong, + = strong, ± = weak, and − = negative, to give an indication of similar agglutination reactions between different haplotypes. Within the UCD line, 003.B congenic haplotypes, RBC from the B*21, B*O, B*Q, and B*R4 haplotypes had agglutination reactions identical to RBC from the 15.B*21 haplotype. RBC from three haplotypes (B*3, B*19, and B*R5) were negative with all of the antisera. RBC from the remaining UCD line 003.B congenic haplotypes were agglutinated by BFIV*13 and , and GH, which had been previously classified as similar to but not identical to B*15, reacted with BF*13 or both BFIV*13 and BFIV*21 antisera. The Fayoumi B*15.2 also reacted with the BFIV*12 antisera. The haplotype B*6 from line G showed weak reactivity with the BFIV*13 antisera. The GH haplotype B*1 (a reference line for B*1; showed a unique pattern, reacting with only the BFIV*21 antisera. The Fayoumi B*5.1 showed an unusual pattern of reactivity, being weakly positive with the BFIV12, BFIV13, and BFIVm126 sera and strongly positive with the BFIV21 and BFIV21m78 sera. None of the B-haplotypes found in the ISU lines showed HA patterns identical with 15.B*21 haplotype, although the ISU Spanish haplotype B*21.1 was very similar. Each BFIV antiserum was diluted from 1:8 to 1:512 and mixed with RBC. The agglutination score is summarized as ++ = very strong, + = strong, ± = weak, and − = negative.
DISCUSSION
The BFIV antisera produced in series E immunizations appear to specifically identify BFIV haplotypes. Specific antisera had minimal cross-reactivity with RBC or peripheral blood leukocytes (PBL) from other B-haplotypes as shown by both HA and flow cytometric analysis. This high level of specificity was due to the identical match of transfected immunizing cell line (RP9, originally derived from a 15I 5 × 7 2 bird) and the host animal (from a cross of 15I 5 × 7 2 ). The only immunogenic difference between the immunizing (donor) cells and the antisera-producing host was the transfected and expressed MHC antigen. The importance of this identical match between the immunizing cell and the serum producer was dramatically shown in the antigenic differences between the series D and series E immunizations. Hosts for the D series antisera were a hybrid F 1 derived from a cross of 15I 5 × 7 1 , whereas the donor cells were derived from a cross of 15I 5 × 7 2 . There was an antigenic difference between lines 7 2 and 7 1 because line 7 2 had a J blood group different from that found in line 7 1 . Antibodies directed against this antigenic difference were seen in D series antisera, which was produced by 15I 5 × 7 1 birds. This reactivity was removable by adsorption. When 15I 5 × 7 2 birds were used as the host animals for antisera production (series E), no J blood group antibodies were induced. The RP9 cell line was developed more than 20 yr ago from an F 1 chicken from a cross of 15I 5 × 7 2 . The high specificity of the E series antisera indicates that no changes have occurred in antigens of these highly inbred lines in the last two decades. Lines 7 1 and 7 2 are derived from the same parental line 7, and the observation of antigenic differences between them stresses the importance of complete matching between the origin of the cells used for immunization and the line used to produce the antiserum. The flow cytometric results of D series antisera with RBC and PBL suggests that the J blood group antigens are expressed on RBC but not on PBL.
Historically, it has been nearly impossible to produce BF specific antisera. It had been hypothesized that BG differences are also required in order to elicit antibodies directed against BF antigens (Hala et al., 1981; Salomonsen et al., 1991) . This study clearly shows that BG differences are not essential for BF antibody production. There are, however, two additional antigens in the immunizing system described here. The immunizing cells (RP9) were originally transformed by using ALV subgroup B virus, and the transfecting vector used produces infectious ALV subgroup A virus. Thus, the immunizing cells contain ALV virus of both subgroups A and B, and the induced antiserum contains antibodies directed against these viruses. In addition, the FLAG epitope is also expressed on the end of the transfected BFIV sequences. The influence of the viral immunogens and the FLAG epitope on the production of BF-specific antibodies is unknown.
The two laboratory-developed mutant forms of BFIV, BFIV*21m78, and BFIV*13m126 were used to induce antibodies. The BFIV*21m78 mutant is identical to BFIV*21 except for amino acids 78 and 81, which were modified from the aspartic acid and arginine found in BFIV*21 to the glycine and glutamic acid found in BFIV*B2 . These amino acids are believed to be involved with antisera cross-reactivity between B*21 and B*5 (Fulton et al., 1996) due to their exposed location on the alpha helix and their presence in both BFIV*21 and BFIV*5 sequences (Hunt and Fulton, 1998) . It was hypothesized that by replacing this epitope with that found in the B*2 haplotype, the cross-reactivity commonly found in B*21 antisera would be eliminated. Use of the BFIV*21m78 mutation clearly eliminated the B*5 cross-reactivity, which confirms the involvement of this epitope in B*21 and B*5 antiserum cross-reactivity.
The second mutant, BFIV*13m126, was identical to BFIV*13 except for the region encoding amino acids 126 to 128. There is a polymorphism unique to B*13 on this exposed antigenic loop (Hunt and Fulton, 1998) . The BFIV*13 sequence codes for aspartic acid, methionine, and lysine, in contrast to glycine, threonine, and methionine for BFIV*12. The BFIV*13 and BFIV*12 sequences have a shared sequence of amino acids from position 147 to 156. This region is on the alpha helix of the MHC molecule and the altered sequence involving 7 of 10 amino acids is unique to BFIV*12 and BFIV*13. It was hypothesized that this region is responsible for the extensive cross-reactivity seen between sera developed for the B*12 and B*13 haplotypes (Fulton et al., 1996; and unpublished) . Altering of the B*13 unique amino acid sequence at amino acid 126 to 129 was expected to result in antisera that were directed against primarily the antigenic region of amino acids 147 to 156 that was shared between BF*12 and BF*13. Adsorption of the BFIV*13-induced antisera with RP9 cells containing BFIV*12 did remove all B*12-specific activity, but considerable BF*13 activity remained. The logical extension of this analysis would be to develop another mutation in which amino acids 126 to 128 are altered in the BFIV*12 sequence to that of the BFIV*13 sequence. Immunization with this mutation followed by subsequent adsorption with BFIV*12 should result in BFIV*13-specific antisera. This would confirm the importance of the amino acids 147 to 156 in B*13-specific antisera.
The utility of this method of antiserum production is further shown by the results of testing the antiserum with RBC of numerous haplotypes from other birds. The antisera gave relatively simple patterns when tested against RBC of various defined haplotypes. The B*24 and B*C haplotypes from the 003.B congenics reacted to both of the BFIV*13-induced sera, which suggests commonality in BF region between the B*13, B*24, and B*C haplotypes. The RBC from the line 003.B*21 birds reacted identically to the 15.B*21 cells. The B*O and B*Q haplotypes both reacted in an identical pattern to that of the 15.B*21 haplotype, which suggests similarity in their BF regions. The BFIV region of the B*Q haplotype has been cloned and sequenced and found to be identical to the BFIV region of haplotype B*21 (Hunt and Fulton, unpublished data) . The antisera results confirmed the sequence information. Testing of the B*R4 and B*R5 recombinants was particularly informative. The B*R4 recombinant contains the BG*15:BF*21 combination . RBC from B*R4 reacted only with BFIV*21-and BFIV*21m78-induced antisera, as expected, because of the presence of BF*21 in the recombinant. The B*R5 recombinant has the reverse situation, containing the BG*21:BF*15 alleles. There was no reactivity of this recombinant haplotype to either of the BFIV*21-induced sera. The sera results are in complete agreement with the known allelic constitution of both recombinants. Further testing would need to use a BFIV*15-induced alloantisera, which has not yet been produced.
The HA data from the 13 inbred lines from ISU show more antisera cross-reactivity, consistent with the wider variety of haplotypes tested. The defined haplotypes of B*12, B*13, and B*15, regardless of the line in which the haplotype exists, react as expected. All three haplotypes from the two exotic breeds (Spanish and Fyoumi) reacted with both of the BFIV*21 antisera. The two Fayoumi haplotypes also reacted with the BFIV*12 and *13 antisera, which suggests some common epitopes. Thus, although we do not know the BFIV types in the ISU lines, most were differentiated with the BFIV-specific antisera. It is tempting to use the serological information to hypothesize the allelic constitution of these other haplotypes. The B*1 haplotype of the GH line appears to be BF*21, the B*6 haplotype from line G is BF*13-like, as is BF*15.1 from line 19. The B*15.1 from lines 8 and GH also have some BF*21-like epitopes. Obtaining the BFIV sequences from these B-haplotypes and using them in the immunization system described here would be extremely useful to better define these Bhaplotypes and develop reagents specific for BFIV typing of these lines, several of which are designated as reference lines for B-haplotypes .
One limitation of this method is the haplotype of the birds used for immunizations. Due to the source of the RP9 cell line (from B*2/*15) and the required identity of the birds used for producing antisera (also B*2/*15), antisera directed against either the B*2 or B*15 haplotypes cannot be produced. These two haplotypes are very commonly found in both laboratory and commercial chickens. Use of a different cell line and its corresponding parental bird for immunizations would be required for production of antisera against these two haplotypes. However, the system described here is highly effective in producing antisera directed against all other B-haplotypes. As more BFIV sequences are cloned (Li et al., 1999) , they could be moved into this vector and used for developing BFIV-specific antisera. These sera could then be used to quickly and easily assay potential BFIV alleles within the numerous MHC haplotypes found in both layer-and broiler-type chickens and, thus, assay commercial chicken strains for Marek's disease-resistant alleles.
Recently, this method was used successfully to produce sera directed against Rfp-Y sequences (Miller et al., 2001) . Sera specific to numerous non-immune function-related epitopes could also be produced by using cloned sequences transferred into the vector and expressed in cell lines.
